Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Reduction in CMV and Adenovirus Viremia after Haploidentical Donor Transplantation Utilizing CD45RA Depletion and NK Cell Infusion

Brandon M. Triplett, MD, Bradley Muller, Guolian Kang, PhD, Shane J Cross, PharmD, Joseph Moen, Mari H Dallas, MD, Christine Hartford, MD, William E. Janssen, PhD, Ping Law, PhD, Ewelina K. Mamcarz, MD, David R Shook, MD, Ashok Srinivasan, MD, Randall T Hayden, MD, Wing Leung, MD PhD

Blood (2015) 126 (23): 624.

https://doi.org/10.1182/blood.V126.23.624.624

Published: 2015

Journal Articles

Tregs Specific for Minor Histocompatibility Antigens

Anandharaman Veerapathran, PhD, Joseph Pidala, MD, MS, Francisca Beato, BS, William E. Janssen, PhD, Xue-Zhong Yu, M.D., M.S., Claudio Anasetti, MD

Blood (2012) 120 (21): 1891.

https://doi.org/10.1182/blood.V120.21.1891.1891

Published: 2012

Journal Articles

Purification and Expansion of Antigen-Specific Human Tregs for Clinical Application Using a Single Step CD25 Positive Selection

Francisca Beato, BS, Anandharaman Veerapathran, PhD, Joseph Pidala, MD, MS, William E. Janssen, PhD, Claudio Anasetti, MD

Blood (2012) 120 (21): 1899.

https://doi.org/10.1182/blood.V120.21.1899.1899

Published: 2012

Journal Articles

Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates,

Jamie Shapiro, PharmD, Janelle Perkins, PharmD, Ryan Bookout, PharmD, Rebecca Tombleson, PharmD, Ernesto Ayala, MD, William E. Janssen, PhD, Claudio Anasetti, MD, Hugo F. Fernandez, MD

Blood (2011) 118 (21): 4060.

https://doi.org/10.1182/blood.V118.21.4060.4060

Published: 2011

Journal Articles

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Joseph Pidala, MD, MS, Jongphil Kim, PhD, Heather Jim, PhD, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed A Kharfan-Dabaja, MD, Brian C. Betts, MD, Taiga Nishihori, MD, Mian Xu, William E. Janssen, PhD, Frederick L Locke, MD, Ernesto Ayala, MD, Lia Perez, MD, Janelle Perkins, PharmD, Teresa Field, MD, PhD, Leonel Ochoa, Melissa Alsina, MD, Claudio Anasetti, MD

Blood (2011) 118 (21): 323.

https://doi.org/10.1182/blood.V118.21.323.323

Published: 2011

Journal Articles

Apheresis of Hematopoietic Progenitor Cell (HPC) From Allogeneic Donors ≥60 Years of Age.

William E. Janssen, PhD, Darlene Rahn, MT, HP, (ASCP), Teresa Field, MD, PhD, Mohamed A Kharfan-Dabaja, MD, Ernesto Ayala, MD, Jose L Ochoa, MD, Martha Hackett, M.P.H., Claudio Anasetti, MD, Hugo F. Fernandez, MD

Blood (2009) 114 (22): 4226.

https://doi.org/10.1182/blood.V114.22.4226.4226

Published: 2009

Journal Articles

Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.

Joseph A. Pidala, MD, Daanish Hoda, Norma Salgado-Vila, Jongphil Kim, PhD, Janelle Perkins, PharmD, Ryan Bookout, PharmD, Teresa Field, MD, PhD, Lia Perez, MD, Ernesto Ayala, MD, J. Leonel Ochoa-Bayona, Jyotishankar Raychaudhuri, Melissa Alsina, MD, John N Greene, MD, William E. Janssen, PhD, Hugo F. Fernandez, MD, Claudio Anasetti, MD, Mohamed A Kharfan-Dabaja, MD

Blood (2009) 114 (22): 2235.

https://doi.org/10.1182/blood.V114.22.2235.2235

Published: 2009

Journal Articles

Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience

Blood (2008) 112 (11): 4435.

https://doi.org/10.1182/blood.V112.11.4435.4435

Published: 2008

Journal Articles

Significant Expansion of Myeloid Derived Suppressor Cells in Patients with High- Risk Breast Cancer Treated with Dose Dense Adjuvant Chemotherapy

James E Talmadge, Elizabeth Reed, MD, Kenneth Cowan, Dmitry Gabrilovich, Phyllis Warkentin, William E. Janssen, PhD, James Wisecarver, James Anderson, Mary Mailliard, Sarah Maas, Orhan Turken, Uger Coskun

Blood (2008) 112 (11): 4653.

https://doi.org/10.1182/blood.V112.11.4653.4653

Published: 2008

Journal Articles

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Todd Alekshun, MD, Christine Mcisaac-Simonelli, RN, Mohamed Kharfan-Dabaja, MD, William Dalton, MD, PhD, Benjamin Djulbegovic, MD, Hugo Fernandez, MD, Daniel M. Sullivan, MD, Ernesto Ayala, MD, Teresa L. Field, MD, Dawn Garrett, LPN, William E. Janssen, PhD, Beth Maddox, RN, Lia Perez, MD, Dawn Kettner, PA, Janelle Perkins, PharmD, Jyoti Raychaudhuri, MD, Claudio Anasetii, MD, Melissa Alsina, MD

Blood (2007) 110 (11): 5131.

https://doi.org/10.1182/blood.V110.11.5131.5131

Published: 2007

NARROW

Reduction in CMV and Adenovirus Viremia after Haploidentical Donor Transplantation Utilizing CD45RA Depletion and NK Cell Infusion

Tregs Specific for Minor Histocompatibility Antigens

Purification and Expansion of Antigen-Specific Human Tregs for Clinical Application Using a Single Step CD25 Positive Selection

Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates,

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Apheresis of Hematopoietic Progenitor Cell (HPC) From Allogeneic Donors ≥60 Years of Age.

Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.

Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience

Significant Expansion of Myeloid Derived Suppressor Cells in Patients with High- Risk Breast Cancer Treated with Dose Dense Adjuvant Chemotherapy

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only